Claire Smith

Claire Smith

Auto-generated profile, based on publicly available information

Claire Smith

MRC Toxicology Unit, Gleeson Building, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCTRACERx Consortium
TRACERx Consortium
KAKhalid AbdulJabbar
Khalid AbdulJabbar
SAShan E Ahmed
Shan E Ahmed
RRRachel Rosenthal
Rachel Rosenthal
MJMariam Jamal-Hanjani
Mariam Jamal-Hanjani
YYYinyin Yuan
Yinyin Yuan

1 August 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
DMDavid Allan Moore
David Allan Moore
MSMarco Sereno
Marco Sereno
MDMadhumita Das
Madhumita Das
JAJuvenal Dario Baena Acevedo
Juvenal Dario Baena Acevedo
SSSamantha Sinnadurai
Samantha Sinnadurai
JQJohn Le Quesne
John Le Quesne

13 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGStefano Grosso
Stefano Grosso
AMAlberto Marini
Alberto Marini
KGKatarina Gyuraszova
Katarina Gyuraszova
JVJohan Vande Voorde
Johan Vande Voorde
ASAristeidis Sfakianos
Aristeidis Sfakianos
AWAnne E Willis
Anne E Willis
Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no ‘druggable’ driver oncogenes associated with MpM. To identify opportunities for management of this disease we have carried out polysome profiling to define the MpM translatome. We show that in MpM there is a selective increase in the translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial morphology and oxygen consumption, and a reprogramming of metabolic outputs. These alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive disease progression. Importantly, we show that inhibition of mRNA translation, particularly through combined pharmacological targeting of mTORC1 and 2, reverses these changes and inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-stage disease. Critically, we show that these pharmacological interventions prolong survival in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable therapeutic option for patients with this incurable disease.

6 November 2020 in Histopathology
Verified
Journal Article
Open access
PDF file
MSMarco Sereno
Marco Sereno
ZHZhangyi He
Zhangyi He
CSClaire R. Smith
Claire R. Smith
JBJuvenal Baena
Juvenal Baena
MDMadhumita Das
Madhumita Das
JQJohn Le Quesne
John Le Quesne
Aims: The decision to consider adjuvant chemotherapy (AC) for non‐small cell lung cancer is currently governed by clinical stage. This study aims to assess other routinely collected pathological variables related to metastasis and survival for their ability to predict the efficacy of AC in lung adenocarcinoma.Methods and results: A retrospective single‐centre series of 620 resected lung non‐mucinous adenocarcinoma cases from 2005 to 2015 was used. Digital images of all slides were subjected to central review, and data on tumour histopathology, AC treatment and patient survival were compiled. A statistical case matching approach was used to counter selection bias. Several high‐risk pathological criteria predict both pathological nodal involvement and early death: positive vascular invasion status (VI+) (HR = 2.10, P < 0.001), positive visceral pleural invasion status (VPI+) (HR = 2.16, P < 0.001), and solid/micropapillary‐predominant WHO tumour type (SPA/MPPA) (HR = 3.29, P < 0.001). Crucially, these criteria also identify patient groups benefiting from AC (VI + HR = 0.69, P = 0.167, VPI + HR = 0.44, P = 0.004, SPA/MPPA HR = 0.36, P = 0.006). Cases showing VI+/VPI+/SPA/MPPA histology in the absence of AC stage criteria were common (170 of 620 total), and 8 had actually received AC. This group showed much better outcomes than equivalent untreated cases in matched analysis (3‐year OS 100.0% versus 31.3%). Inclusion of patients with VI+/VPI+/SPA/MPPA histology would increase AC‐eligible patients from 51.0% to 84.0% of non‐mucinous tumours in our cohort.Conclusions: Our data provide preliminary evidence that the consideration of AC in patients with additional high‐risk pathological indicators may significantly improve outcomes in operable lung adenocarcinoma, and that AC may be currently underused.

13 December 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
EDEsraa Al Dujaily
Esraa Al Dujaily
JBJuvenal Baena
Juvenal Baena
MDMadhumita Das
Madhumita Das
MSMarco Sereno
Marco Sereno
CSClaire Smith
Claire Smith
JQJohn Le Quesne
John Le Quesne
Statins have anticancer properties by acting as competitive inhibitors of the mevalonate pathway. They also have anti-inflammatory activity, but their role in suppressing inflammation in a cancer context has not been investigated to date. We have analyzed the relationship between statin use and tumor-associated macrophages (TAMs) in a cohort of 262 surgically resected primary human lung adenocarcinomas. TAMs were evaluated by multiplex immunostaining for the CD68 pan-TAM marker and the CD163 protumorigenic TAM marker followed by digital slide scanning and partially automated quantitation. Links between statin use and tumor stage, virulence, and cancer-specific survival were also investigated in a wider cohort of 958 lung adenocarcinoma cases. All statistical tests were two-sided. We found a statin dose-dependent reduction in protumorigenic TAMs (CD68+CD163+) in both stromal (P = .021) and parenchymal (P = .003) compartments within regions of in situ tumor growth, but this association was lost in invasive regions. No statistically significant relationship between statin use and tumor stage was observed, but there was a statin dose-dependent shift towards lower histological grade as assessed by growth pattern (P = .028). However, statin use was a predictor of slightly worse cancer-specific survival (P = .032), even after accounting for prognostic variables in a multivariable Cox proportional hazards survival model (hazard ratio = 1.38, 95% confidence interval = 1.04 to 1.84). Statin use is associated with reduced numbers of protumorigenic TAMs within preinvasive lung adenocarcinoma and is related to reduced tumor invasiveness, suggesting a chemo-preventive effect in early tumor development. However, invasive disease is resistant to these effects, and no beneficial relationship between statin use and patient outcome is observed.

1 January 2016 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
MDM. Das
M. Das
DMD.A. Moore
D.A. Moore
MSM. Sereno
M. Sereno
CSC. Smith
C. Smith
RHR. Hastings
R. Hastings
JQJ. Le Quesne
J. Le Quesne